TargetBeta
CSF3R
colony stimulating factor 3 receptor · also GCSFR, G-CSF-R, CD114 · CD molecules
3 programs in company-led studies act on CSF3R, from 3 companies: 0 in phase 3, 2 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| pegfilgrastimrule | Amgen | phase 4 | 522 running | CSF3 | ChEMBL |
| Filgrastimrule | Pfizer | phase 4 | 332 running | – | ChEMBL |
| anumigilimabrule | CSL | phase 2 | 41 running | – | ChEMBL |
Also acted on by the same programs
Conditions their studies are in
- Breast Neoplasms, 2 programs
- Lymphoma, Non-Hodgkin, 2 programs
- Neutropenia, 2 programs
- Anemia, Sickle Cell, 1 program
- COVID-19, 1 program
- Febrile Neutropenia, 1 program
- Lymphoma, 1 program
- Multiple Myeloma, 1 program
- ST Elevation Myocardial Infarction, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Apr 7, 2027Filgrastim · Pfizer · phase 4 · NCT07877467
- Aug 15, 2028anumigilimab · CSL · phase 2 · NCT07224360
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.